News

20th November 2024

BerGenBio Appoints Olav Hellebø as CEO

13th November 2024

BerGenBio Third Quarter Results 2024

6th November 2024

BerGenBio ASA: Invitation to third quarter 2024 results webcast

10th October 2024

CEO Martin Olin steps down

10th October 2024

BerGenBio ASA: Minutes from Extraordinary General Meeting

7th October 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

19th September 2024

BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

9th September 2024

BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

21st August 2024

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress